Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Standard Triple Therapy as a Remedy for Treatment of Helicobacter pylo-ri Infection: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Thu Feb 29 06:27:32 2024

(2023) Standard Triple Therapy as a Remedy for Treatment of Helicobacter pylo-ri Infection: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Current Reviews in Clinical and Experimental Pharmacology. pp. 167-181. ISSN 27724328 (ISSN)

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: H. pylori infection, one of the most prevalent infectious diseases, can cause severe health problems. Therefore, it seems to be crucial to effectively counter the H. pylori infection with a well-tolerated eradication regimen. However, since the discovery of H. pylori, the optimal treatment for this disease is still unclear and remains controversial. Objectives: The present study aims to estimate the efficacy of standard triple therapy for eradicating H. pylori by systematic review and meta-analysis. Methods: We identified randomized clinical trials RCTs involving triple therapy PPIAC/M Omeprazole, Amoxicillin, and Clarithromycin/Metronidazole in the first-line treatment of H. pylori infection and reported eradication rate through electronic and manual searches in PubMed, ISI, EM-BASE, the Cochrane Central Register, and Scopus databases. Data were analyzed using the random effect model, and the Cochrane Q test and I2 statistics were used to assess heterogeneity. Statistical analyses were performed using STATA version 12. Results: Forty-seven RCTs PPIAC: 40 RCTs and PPIAM: 7 RCTs with 4,938 patients selected as el-igible for the final analysis. Per-protocol eradication rate was 80% 95% CI: 74-84 and 80% 95% CI: 73-87 for PPIAC and PPIAM regimens, respectively. The eradication rate for PPIAC and PPIAM regimens was 83% 95% CI: 70%-95% and 83% 95% CI: 75%-90% and also 77% 95% CI: 68%-88% and 78% 95% CI: 69%-88%, respectively. Based on different treatment durations, the pooled estimates of PP per-protocol analysis treatment outcomes were found the highest in 14-day treatment in both regimens. Conclusion: Standard triple therapy PPIAC/M is recommended to be an effective and safe regimen, although adequate data are not available to suggest PPIAC/M as the first-line therapy for H. Pylori in-fection. Interestingly, our analysis demonstrated that PPIAC/M regimens were more effective in Asian than European populations. © 2023 Bentham Science Publishers.

Item Type: Article
Creators:
CreatorsEmail
Kiani, F.UNSPECIFIED
Khademolhosseini, S.UNSPECIFIED
Fathi, M.UNSPECIFIED
Tavasol, A.UNSPECIFIED
Mohammadi, J.UNSPECIFIED
Dousti, M.UNSPECIFIED
Hoseini, J. E.UNSPECIFIED
Keywords: first-line treatment gastrointestinal diseases Helicobacter Pylori eradication infection therapy lymphoma standard triple therapy amoxicillin clarithromycin metronidazole omeprazole antiinfective agent proton pump inhibitor antibiotic therapy Article Asia clinical protocol Cochrane Library drug efficacy drug safety drug tolerability Embase European Helicobacter infection human infection control Medline meta analysis outcome assessment race difference randomized controlled trial (topic) Scopus systematic review treatment duration combination drug therapy Helicobacter pylori Anti-Bacterial Agents Drug Therapy, Combination Helicobacter Infections Humans Proton Pump Inhibitors Randomized Controlled Trials as Topic
Divisions:
Page Range: pp. 167-181
Journal or Publication Title: Current Reviews in Clinical and Experimental Pharmacology
Journal Index: Scopus
Volume: 18
Number: 2
Identification Number: https://doi.org/10.2174/2772432817666220317152544
ISSN: 27724328 (ISSN)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4291

Actions (login required)

View Item View Item